Revenue and net profit declined sharply year-over-year due to lower caffeine prices and increased R&D spending, but the company expanded into innovative biologics and launched a new PD-1 antibody drug. Gross margin and cash flow also fell, while major investments and share buybacks were completed.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.